Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy.
about
Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Current WHO guidelines and the ...... eted therapy to immunotherapy.
@en
Current WHO guidelines and the ...... non-small cell lung carcinoma
@nl
type
label
Current WHO guidelines and the ...... eted therapy to immunotherapy.
@en
Current WHO guidelines and the ...... non-small cell lung carcinoma
@nl
prefLabel
Current WHO guidelines and the ...... eted therapy to immunotherapy.
@en
Current WHO guidelines and the ...... non-small cell lung carcinoma
@nl
P2093
P2860
P1476
Current WHO guidelines and the ...... eted therapy to immunotherapy.
@en
P2093
Edward Gabrielson
Frederic Askin
Lais Osmani
Qing Kay Li
P2860
P356
10.1016/J.SEMCANCER.2017.11.019
P577
2017-11-25T00:00:00Z